Literature DB >> 10940064

Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application.

A Orenstein1, J Haik, J Tamir, E Winkler, H Trau, Z Malik, G Kostenich.   

Abstract

BACKGROUND: Photodynamic therapy (PDT) with topical application of 5-aminolevulinic acid (ALA) is a new and effective modality for treatment of superficial basal and squamous cell carcinomas.
OBJECTIVE: We present the kinetics of ALA-induced protoporphyrin IX (PP) accumulation and the results of ALA PDT treatment on two patients with different stages (stage I and stage III) of mycosis fungoides (MF)-type cutaneous T-cell lymphoma (CTCL).
METHODS: ALA-Decoderm cream was applied to the lesions for 16 hours. Spectrofluorescence measurements of PP accumulation were carried out before, during, and 1 hour after photoirradiation (580-720 nm) using the VersaLight system.
RESULTS: Different patterns of PP fluorescence kinetics were observed in patients with early and advanced stages of the disease. During photoirradiation the intensity of fluorescence decreased depending on the lesion thickness. One hour after the photoirradiation procedure no PP fluorescence was observed in the stage I MF lesion, while in the thick stage III MF lesions, PP fluorescence reappeared; after an additional 10-15 minutes of irradiation PP fluorescence disappeared. Complete response with excellent cosmetic results was observed in the stage I lesion after a single irradiation with a light dose of 170 J/cm2; in five stage III lesions, complete response was achieved after fractionated irradiation with a total light dose of 380 J/cm2 (follow-up at 27 and 24 months, respectively).
CONCLUSION: The results showed a high response of both stage I and stage III MF lesions to ALA PDT. This modality appears to be very effective and can be used successfully for MF treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10940064     DOI: 10.1046/j.1524-4725.2000.00056.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  7 in total

1.  Monitoring Pc 4 photodynamic therapy in clinical trials of cutaneous T-cell lymphoma using noninvasive spectroscopy.

Authors:  Tammy K Lee; Elma D Baron; Thomas H Foster
Journal:  J Biomed Opt       Date:  2008 May-Jun       Impact factor: 3.170

Review 2.  Therapeutic advances in cutaneous T-cell lymphoma.

Authors:  Oleg E Akilov; Larisa Geskin
Journal:  Skin Therapy Lett       Date:  2011-02

Review 3.  Innovative therapy of cutaneous T-cell lymphoma: beyond psoralen and ultraviolet light and nitrogen mustard.

Authors:  Brian Poligone; Peter Heald
Journal:  Dermatol Clin       Date:  2010-07       Impact factor: 3.478

4.  Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial.

Authors:  Elma D Baron; Christi L Malbasa; Diana Santo-Domingo; Pingfu Fu; Janine D Miller; Kaija K Hanneman; Andrew H Hsia; Nancy L Oleinick; Valdir C Colussi; Kevin D Cooper
Journal:  Lasers Surg Med       Date:  2010-12       Impact factor: 4.025

5.  Nuclear distribution of porphobilinogen deaminase (PBGD) in glioma cells: a regulatory role in cancer transformation?

Authors:  L Greenbaum; Y Gozlan; D Schwartz; D J Katcoff; Z Malik
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

6.  Emerging treatment options for early mycosis fungoides.

Authors:  Montserrat Fernandez-Guarino
Journal:  Clin Cosmet Investig Dermatol       Date:  2013-02-18

7.  Mapping of oxidative stress responses of human tumor cells following photodynamic therapy using hexaminolevulinate.

Authors:  Lina Cekaite; Qian Peng; Andrew Reiner; Susan Shahzidi; Siri Tveito; Ingegerd E Furre; Eivind Hovig
Journal:  BMC Genomics       Date:  2007-08-13       Impact factor: 3.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.